Cipla Share Price in Focus; Falls 1%

On December 4, 2024, Cipla Ltd’s share price (NSE: CIPLA) was trading 1.14% lower at ₹1,516.45 at 10:30 AM on the NSE. The stock opened at ₹1,530, down from ₹1,530 at the previous close.

Promoters Sell Stake, Investors Acquire Cipla Shares

In a recent development, Samina Hamied and Rumana Hamied, the promoters of Cipla, sold their combined 1.72% stake in the company, worth ₹2,111 crore, through open market transactions.

A group of investors, including the Singapore government, Societe Generale, Abu Dhabi Investment Authority, BNP Paribas, BofA Securities, Citigroup, Morgan Stanley, Goldman Sachs, Norges Bank, UBS, and Copthall Mauritius, acquired these shares.

According to data from the National Stock Exchange, Samina sold 89.54 lakh shares, representing a 1.11% stake, while Rumana offloaded 49.43 lakh shares, accounting for 0.61% of the company.

Cipla Q2 FY25 Financial Highlights

Cipla, reported a 15.2% on-year growth in its consolidated profit at ₹1,303 crore for Q2 FY25, compared to ₹1,131 crore in the same period last year.

The company’s revenue from product sales grew by 5.6%, amounting to ₹6,961 crore, up from ₹6,589 crore in Q2 FY24.

Additionally, Cipla’s EBITDA margin hit a high of 26.7%, reflecting efficiency gains during the quarter.

About Cipla

Cipla Ltd. is one of India’s leading multinational pharmaceutical companies, known for manufacturing a wide range of high-quality medicines. Founded in 1935 by Dr. K.A. Hamied, the company has grown into a global healthcare provider with a significant presence in over 150 countries. Cipla’s portfolio spans various therapeutic areas, including respiratory, cardiovascular, oncology, and anti-retroviral medications.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.